Researchers from Thor Therapeutics Inc. and collaborators reported the efficacy of A-427, a CNS-targeted antisense oligonucleotide (ASO) that selectively suppresses Gfral expression, in preclinical models of cancer-associated cachexia. The brainstem-restricted receptor GFRAL, which mediates the cachexia-inducing effects of tumor-derived GDF15, has emerged as a translational target for therapies designed to counteract tumor-associated wasting and weight loss.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has discovered new peroxisome proliferator-activated receptor γ (PPARγ) modulators potentially useful for the treatment of bladder cancer.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Tianjin Hengrui Medicine Co. Ltd. have disclosed new fibroblast activation protein-α (FAPα) inhibitors covalently linked to radiolabeled chelating agents through a linker potentially useful for the treatment of cancer, inflammatory, cardiovascular disorders and more.
Prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA) are highly expressed in prostate tumors and exhibit greater prostate specificity than other prostate cancer antigens, reducing the risk of off-target immune responses. Researchers from Theravectys SA and Institut Pasteur reported preclinical efficacy data for Lenti-PROST-02, a novel lentiviral immunotherapy encoding immunogenic regions of PAP and PSA for the treatment of prostate cancer.
Core Biomedicine Inc. has completed a $21 million series A financing and been awarded a Japan Agency for Medical Research and Development (AMED) grant to advance its lead programs through discovery and early clinical development.
Researchers from Jacobio Pharmaceuticals Co. Ltd. recently presented preclinical data on JAB-BX600, an EGFR-directed antibody-drug conjugate (ADC) that selectively delivers a KRAS G12D inhibitor to tumor cells, allowing dual inhibition of the EGFR-KRAS pathway.
Shanghai Jeyou Pharmaceutical Co. Ltd. has discovered new ATP-dependent RNA helicase A (DHX9) inhibitors potentially useful for the treatment of cancer, viral infection and autoimmune disease.
Shanghai Escugen Biotechnology Co. Ltd. has identified new antibody-drug conjugates (ADCs) comprising an antibody targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to a cytotoxic drug potentially useful for the treatment of cancer.
Promatix Biosciences Ltd. has been awarded an Innovate UK Biomedical Catalyst grant to support development of its lead program, PBS-293-exatecan, a first-in-class EGFR x EphA2 cis-bispecific antibody-drug conjugate.
Exeliris Co. Ltd. and Lin Gang Laboratory have reported phosphatidylinositol 3-kinase α (PI3Kα) inhibitors that are potentially useful for the treatment of cancer.
RSS
